Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges
Animal Models and Experimental Medicine · 2025
DOI: 10.1002/ame2.70018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Linlin Zheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Changping Laboratory, Beijing, China. Hauptthemen laut MEDLINE: COVID-19, mRNA Vaccines, RNA, Messenger, Viral Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grants from the Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Respiratory infectious diseases frequently erupt on a global scale, with RNA viruses, such as SARS‐CoV‐2, RSV, and influenza viruses, posing challenges to vaccine development due to their high mutation rates. Traditional vaccine development cycles are lengthy and struggle to keep pace with rapidly evolving viruses, whereas messenger RNA (mRNA) vaccines have demonstrated significant advantages due to their short development periods, straightforward production, and low costs. After the outbreak of the COVID‐19 pandemic, multiple mRNA vaccines, including Pfizer‐BioNTech and Moderna, rapidly received emergency use authorization, validating their feasibility. The Nobel Prize in Physiology or Medicine in 2023 was awarded to Katalin Karikó and Drew Weissman, underscoring the efficacy of mRNA vaccine technology. In 2024, the U.S. Food and Drug Administration (FDA) approval of Moderna's respiratory syncytial virus (RSV) mRNA vaccine marked the immense potential of mRNA technology in vaccine innovation. This review article summarizes the design, clinical research, and future challenges of mRNA vaccines for respiratory viruses, delving into antigen design, mRNA delivery systems, and advancements in vaccines for multiple respiratory viruses, including innovations in self‐amplifying mRNA and circular mRNA vaccines. Additionally, the development of combination vaccines is underway, aiming to provide protection against multiple viruses through a single administration. Despite the significant progress in mRNA vaccine development, challenges remain regarding raw material costs, stability, and delivery efficiency. In the future, with technological advancements and the accumulation of clinical experience, the design strategies and delivery systems of mRNA vaccines are expected to be continuously optimized, thereby enhancing their safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changping Laboratory, Beijing, China.
- National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
ORCID-Profile: Linlin Zheng
Förderung
- Grants from the Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zheng, L., & Feng, H. (2025). Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.70018
Vancouver
Zheng L, Feng H. Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.70018
BibTeX
@article{Zheng2025,
author = {Zheng, Linlin and Feng, Han},
title = {Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges},
journal = {Animal Models and Experimental Medicine},
year = {2025},
doi = {10.1002/ame2.70018}
}
EUVIMED